BCM
NEO icon

Bluefin Capital Management’s NeoGenomics NEO Stock Holding History

Bluefin Capital Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$18K – 818
2021
Q1 		$18K Buy
+50,000
New +$2.6M ﹤0.01% 673

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bluefin Capital Management's NEO Position: Q4 2022 in Review

Bluefin Capital Management sold out of NeoGenomics (NEO) in Q4 2022, closing a stake of 15,853 shares — an estimated $136K sold.

Bluefin Capital Management first reported a position in NEO in Q3 2022 and held it in 1 quarter. The position peaked at $136K in Q3 2022. 244 funds tracked by Wall St. Rank hold NEO as of Q4 2022.

  • Bluefin Capital Management reported no remaining NeoGenomics position as of Q4 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 15,853 NeoGenomics shares in Q4 2022, an estimated $136K.
  • Bluefin Capital Management first reported a position in NeoGenomics in Q3 2022 and held it in 1 quarter.
  • Bluefin Capital Management's NeoGenomics position peaked at $136K in Q3 2022.
  • 244 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2022.

Based on Bluefin Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.